2029 Biopharma Pharma 
European Pharmaceutical Review
MAY 20, 2024
It is anticipated that operations will be ready to commence from 2029. Biologics market According to Sigma Mostafa, PhD, Chief Scientific Officer at the contract development and manufacturing organisation (CDMO) KBI Biopharma, one of the key challenges in the biologics field is the “manufacturability of the drugs being developed”.
MedCity News
MAY 20, 2024
AstraZeneca aims to open the facility in 2029. The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. The post AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
JANUARY 8, 2024
Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. billion in 2029 revenues.
Pharmaceutical Technology
APRIL 4, 2023
According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. The biopharma aims to start the study as soon as the IND is cleared by the FDA. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018.
Clarivate
OCTOBER 17, 2024
A second Trump administration would like face pushback if it abandoned or overturned the drug-pricing reforms of the Inflation Reduction Act, which includes numerous pieces that will prove popular with seniors, even as the industry faces price negotiations on top drugs, long an industry non-starter.
Expert insights. Personalized for you.
98 
Let's personalize your content